Equities
Health CareMedical Equipment and Services
  • Price (USD)236.22
  • Today's Change-5.85 / -2.42%
  • Shares traded274.56k
  • 1 Year change+30.19%
  • Beta0.5041
Data delayed at least 15 minutes, as of Nov 12 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy6
Outperform6
Hold7
Sell0
Strong Sell0

Share price forecast in USD

The 17 analysts offering 12 month price targets for Penumbra Inc have a median target of 238.00, with a high estimate of 260.00 and a low estimate of 190.00. The median estimate represents a -1.68% decrease from the last price of 242.07.
High7.4%260.00
Med-1.7%238.00
Low-21.5%190.00

Earnings history & estimates in USD

On Oct 30, 2024, Penumbra Inc reported 3rd quarter 2024 earnings of 0.85 per share. This result exceeded the 0.69 consensus of the 17 analysts covering the company and exceeded last year's 3rd quarter results by 26.87%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate+14.07%
Penumbra Inc reported annual 2023 earnings of 2.09 per share on Feb 22, 2024.
Average growth rate+391.98%
More ▼

Revenue history & estimates in USD

Penumbra, Inc. had 3rd quarter 2024 revenues of 301.04m. This bettered the 297.41m consensus of the 17 analysts covering the company. This was 24.71% above the prior year's 3rd quarter results.
Average growth rate+2.74%
Penumbra, Inc. had revenues for the full year 2023 of 1.06bn. This was 24.95% above the prior year's results.
Average growth rate+18.43%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.